(Lung Cancer) Lorlatinib: What the CROWN Trial Reported
(Lung Cancer) Lorlatinib: What the CROWN Trial Reported
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Lorlatinib: What the CROWN Trial Reported
- June 10, 2022
- 1 min read
On May 23, 2022, Benjamin J. Solomon et al. from Peter MacCallum Cancer Centre published results in the Journal of Clinical Oncology on the post-hoc analysis of the CROWN Phase III clinical trial evaluating the efficacy and safety of ALK inhibitor ALK-targeted drug as first-line treatment for ALK fusion gene mutation-positive advanced non-small cell lung cancer patients.
The CROWN Phase III clinical trial randomized ALK fusion gene mutation-positive advanced non-small cell lung cancer patients in a 1:1 ratio into the ALK-targeted drug group (100 mg once daily) and the Crizotinib group (250 mg twice daily). The primary endpoint was progression-free survival.
The trial results showed that the 12-month progression-free survival rate in patients with brain metastases was 78% for the ALK-targeted drug group / 22% for the Crizotinib group. In patients without brain metastases, the 12-month progression-free survival rate was 78% for the ALK-targeted drug group / 45% for the Crizotinib group. The 12-month incidence of central nervous system disease progression in patients with brain metastases was 7% for the ALK-targeted drug group / 72% for the Crizotinib group. In patients without brain metastases, the 12-month incidence of central nervous system disease progression was 1% for the ALK-targeted drug group / 18% for the Crizotinib group.
Regarding safety, the adverse event rate in the ALK-targeted drug group was 35%, with most being grade 1 adverse events.
Based on the post-hoc analysis of the CROWN trial, Benjamin J. Solomon et al. stated that ALK inhibitor ALK-targeted drug as first-line treatment for ALK fusion gene mutation-positive advanced non-small cell lung cancer patients improved progression-free survival and suppressed central nervous system disease progression.
Source: https://ascopubs.org/doi/full/10.1200/JCO.21.02278
-
Investigational drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.